Poniard Pharmaceuticals Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Poniard Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Poniard Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Poniard Pharmaceuticals is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Total Cashflows From Investing Activities | 24 M |
Poniard |
Poniard Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Poniard Pharmaceuticals on December 24, 2024 and sell it today you would earn a total of 100.00 from holding Poniard Pharmaceuticals or generate -100.0% return on investment over 90 days. Poniard Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Poniard, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Poniard Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Poniard Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Poniard Pharmaceuticals, and traders can use it to determine the average amount a Poniard Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PARD |
Based on monthly moving average Poniard Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Poniard Pharmaceuticals by adding Poniard Pharmaceuticals to a well-diversified portfolio.
Poniard Pharmaceuticals Fundamentals Growth
Poniard Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Poniard Pharmaceuticals, and Poniard Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Poniard Pink Sheet performance.
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Cash And Equivalents | 1.98 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.57 M | ||||
| Debt To Equity | 0.53 % | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (24.28 M) | ||||
| Earnings Per Share | (3.79) X | ||||
| Total Asset | 11.64 M | ||||
| Retained Earnings | (438.94 M) | ||||
| Current Asset | 5.22 M | ||||
| Current Liabilities | 1.62 M | ||||
Things to note about Poniard Pharmaceuticals performance evaluation
Checking the ongoing alerts about Poniard Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Poniard Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Poniard Pharmaceuticals is not yet fully synchronised with the market data | |
| Poniard Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Poniard Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Poniard Pharmaceuticals currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Poniard Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Poniard Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Poniard Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poniard Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poniard to invest in growth at high rates of return. When we think about Poniard Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Poniard Pharmaceuticals currently holds about 1.98 M in cash with (24.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. |
- Analyzing Poniard Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Poniard Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Poniard Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Poniard Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Poniard Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Poniard Pharmaceuticals' pink sheet. These opinions can provide insight into Poniard Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |